Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Zero-Commission Trading: Risks and Opportunities, Part 1

Part 1: What It All Means for Investors: Online brokers as investments. There's a financial war going on, and the fallout is causing tremors well beyond Wall Street. Investors armed with the right information can make the new zero-commissions standard work to their ad...
Streetwise Reports | November 21, 2019 |

Updated PFS Expected to Show Improved Economics for Australia Gold Project

The reasons for the better scenario are discussed in a ROTH Capital Partners report. In a May 29 research note, ROTH Capital Partners analyst Jake Sekelsky reported that recent additional metallurgical test results from Vista Gold Corp.'s (VGZ:NYSE.MKT; VGZ...
Streetwise Reports | June 4, 2019 |

US Biopharma to Launch Phase 3 Trial in Bacterial Vaginosis

Daré Bioscience's study, its prospects and the indication's U.S. market opportunity are discussed in a ROTH Capital Partners report. In a May 15 research note, ROTH Capital Partners analyst Yasmeen Rahimi reviewed why the outlook is positive for Daré Bioscience In...
Streetwise Reports | May 21, 2020 |

A Rate Cut in Question, Falling Oil Discoveries and Record Silver Inflows

Will he or won’t he? That seems to be the question on a lot of traders and investors’ minds today with regard to Federal Reserve chair Jay Powell. An October rate cut appeared back on the table after disappointing economic news was re...
Frank Holmes | October 7, 2019 |

Here’s What the Market Did EVERY TIME the Fed Cut Rates During an Economic Expansion

The market is now at record highs, and unemployment is way down. Even so, a U.S. rate cut is expected as early as this week. During his congressional testimony last week, Federal Reserve Chairman Jerome Powell raised concerns over slower global growth and trade tensions, ...
Frank Holmes | July 15, 2019 |

Buzz on the Bullboards: Rate hikes and you

News for traders this week has revolved around the Federal Reserve raising its benchmark interest rate by three-quarters of a point for a fourth straight time.
Jonathon Brown | November 3, 2022 |

Follow the Trend Lines, Not the Headlines

“Follow the trend lines, not the headlines,” President Bill Clinton once said. I’m a news junkie myself, but I guarantee you I wouldn’t be where I am today had I based every one of my investment decisions on what the talki...
Frank Holmes | July 29, 2019 |

Gold Projected to Beat the Market in 2020

Gold will outperform the S&P 500 Index in 2020. That’s one of several projections made by CLSA in its just-released “Global Surprises 2020” report. The Hong Kong investment firm has an impressive track record when it comes to maki...
Frank Holmes | February 10, 2020 |

Growth Is Crushing Value Right Now, but Take a Long-Term Horizon

Investors are betting on growth stocks over value stocks by a wider spread right now than at any other time since at least 1990, including during the tech bubble. The ratio between the Russell 1000 Growth Index and Russell 1000 Value Index reached a series high of 1....
Frank Holmes | May 27, 2020 |

NurExone Biologic announces important test results

By Brad Sorensen, CFA, Zacks Research. NurExone Biologic (TSXV:NRX; OTCQB:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries, while also conducting preclinical tests for other conditions that ExoPTEN m...
Research | 11 days ago |
1 2 3 4 5 6 7 8 9 10 ...